References
- Migone TS, Zhang J, Luo X, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002;16:479–492.
- Valatas V, Kolios G, Bamias G. TL1A (TNFSF15) and DR3 (TNFRSF25): a co-stimulatory system of cytokines with diverse functions in gut mucosal immunity. Front Immunol. 2019;10. DOI:https://doi.org/10.3389/fimmu.2019.00583
- Jin S, Chin J, Seeber S, et al. TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+CD161+ T cells to exacerbate gut inflammation. Mucosal Immunol. 2013;6:886–899.
- Meylan F, Hawley ET, Barron L, et al. The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells. Mucosal Immunol. 2014;7:958–968.
- Richard AC, Ferdinand JR, Meylan F, et al. The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator. J Leukoc Biol. 2015;98:333–345.
- Han F, Song J, Jia W, et al. TL1A primed dendritic cells activation exacerbated chronic murine colitis. Life Sci. 2020;262:118220.
- Li Z, Buttó LF, Buela KA, et al. Death receptor 3 signaling controls the balance between regulatory and effector lymphocytes in SAMP1/YitFc mice with crohn’s disease-like ileitis. Front Immunol. 2018;9:362.
- Tougaard P, Skov S, Pedersen AE, et al. TL1A regulates TCRγδ+ intraepithelial lymphocytes and gut microbial composition. Eur J Immunol. 2015;45:865–875.
- Pappu BP, Borodovsky A, Zheng TS, et al. TL1A–DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med. 2008;205:1049–1062.
- Bamias G, Martin C, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003;171:4868–4874.
- Castellanos JG, Woo V, Viladomiu M, et al. Microbiota-induced TNF-like Ligand 1A drives group 3 innate lymphoid cell-mediated barrier protection and intestinal T cell activation during colitis. Immunity. 2018;49:1077–1089.e5.
- Liu JZ, Van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979–986.
- Ditrich F, Blümel S, Biedermann L, et al. Genetic risk factors predict disease progression in Crohn’s disease patients of the Swiss inflammatory bowel disease cohort. Therap Adv Gastroenterol. 2020;13:175628482095925.
- Banfield C, Rudin D, Bhattacharya I, et al. First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects. Br J Clin Pharmacol. 2020;86:812–824.
- Danese S, Klopocka M, Scherl EJ, et al. Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study. Clin Gastroenterol Hepatol. 2021;19:2324–2332.e6.
- Hassan-Zahraee M, Ye Z, Xi L, et al. Antitumor necrosis factor-like ligand 1A therapy targets tissue inflammation and fibrosis pathways and reduces gut pathobionts in ulcerative colitis. Inflamm Bowel Dis. 2022;28:434–446.
- Jia L-G, Bamias G, Arseneau KO, et al. A novel role for TL1A/DR3 in protection against intestinal injury and infection. J Immunol. 2016;197(1):377–386.
- Konsta M, Bamias G, Tektonidou MG, et al. Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. Rheumatology. 2013;52(3):448–451.
- Li L, Fu L, Lu Y, et al. TNF-like ligand 1A is associated with the pathogenesis of psoriasis vulgaris and contributes to IL-17 production in PBMCs. Arch Dermatol Res. 2014;306(10):927–932.
- Bamias G, Filidou E, Goukos D, et al. Crohn’s disease-associated mucosal factors regulate the expression of TNF-like cytokine 1A and its receptors in primary subepithelial intestinal myofibroblasts and intestinal epithelial cells. Transl Res. 2017;180:118–130.e2.
- Shih DQ, Zheng L, Zhang X, et al. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis. Mucosal Immunol. 2014;7(6):1492–1503.